Mark D. Pegram

41.4k total citations · 7 hit papers
221 papers, 23.8k citations indexed

About

Mark D. Pegram is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Mark D. Pegram has authored 221 papers receiving a total of 23.8k indexed citations (citations by other indexed papers that have themselves been cited), including 172 papers in Oncology, 96 papers in Radiology, Nuclear Medicine and Imaging and 51 papers in Molecular Biology. Recurrent topics in Mark D. Pegram's work include HER2/EGFR in Cancer Research (125 papers), Monoclonal and Polyclonal Antibodies Research (80 papers) and Cancer Treatment and Pharmacology (65 papers). Mark D. Pegram is often cited by papers focused on HER2/EGFR in Cancer Research (125 papers), Monoclonal and Polyclonal Antibodies Research (80 papers) and Cancer Treatment and Pharmacology (65 papers). Mark D. Pegram collaborates with scholars based in United States, Germany and United Kingdom. Mark D. Pegram's co-authors include Dennis J. Slamon, José Baselga, W. Eiermann, Brian Leyland‐Jones, Alex Bajamonde, Steven Shak, Virginia Paton, Larry Norton, Thomas Fleming and Janet Wolter and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Advanced Materials.

In The Last Decade

Mark D. Pegram

214 papers receiving 23.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 8.4k citations Dennis J. Slamon, Mark D. Pegram et al. profile →
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

2012 2.7k citations Sunil Verma, Mark D. Pegram et al. profile →
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

1998 848 citations Mark D. Pegram, José Baselga et al. Journal of Clinical Oncology profile →
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

2009 766 citations Xavier Pivot, Michael F. Press et al. Journal of Clinical Oncology profile →
Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

2006 711 citations Gottfried E. Konecny, Mark D. Pegram et al. Cancer Research profile →
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1999 540 citations Mark D. Pegram, Gail D. Lewis Phillips et al. profile →
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

2017 465 citations Sunil Verma, Mark D. Pegram et al. profile →

Peers

Countries citing papers authored by Mark D. Pegram

Since Specialization

Citations

This map shows the geographic impact of Mark D. Pegram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. Pegram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. Pegram more than expected).

Fields of papers citing papers by Mark D. Pegram

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark D. Pegram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. Pegram. The network helps show where Mark D. Pegram may publish in the future.

Co-authorship network of co-authors of Mark D. Pegram

This figure shows the co-authorship network connecting the top 25 collaborators of Mark D. Pegram. A scholar is included among the top collaborators of Mark D. Pegram based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark D. Pegram. Mark D. Pegram is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2− Advanced Breast Cancer 2025 ·Oncology and Therapy ·Sarah Sammons, DA Yardley, Priyanka Sharma, Vijayakrishna K. Gadi, Mark D. Pegram, (unknown), Huilin Hu, (unknown), (unknown)	0
2	Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd). 2024 ·Journal of Clinical Oncology ·Mark D. Pegram, Carmen Calfa, Christopher S. Chen, Alfonso Cortés, Arielle L. Heeke, Irene Kang, Barbara Pistilli, Paula R. Pohlmann, Hope S. Rugo, Cristina Saura, Cécile Vicier, Cecelia I. Pearson, Milan Mangeshkar, (unknown), Michael N. Alonso, Dawn Colburn, Edith A. Perez, Joshua Z. Drago	1
3	Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer 2023 ·npj Breast Cancer ·Giuseppe Curigliano, Rebecca Dent, Antonio Llombart‐Cussac, Mark D. Pegram, Lajos Pusztai, Nicholas C. Turner, Giuseppe Viale	11
4	Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data 2023 ·npj Breast Cancer ·Nancy U. Lin, Priya Kumthekar, Solmaz Sahebjam, Nuhad K. Ibrahim, (unknown), (unknown), Alan Nicholas, (unknown), Mark D. Pegram	9
5	A careful reassessment of anthracycline use in curable breast cancer 2021 ·npj Breast Cancer ·Sara A. Hurvitz, Nicholas P. McAndrew, Aditya Bardia, Michael F. Press, Mark D. Pegram, John Crown, Peter A. Fasching, Bent Ejlertsen, Eric H. Yang, John A. Glaspy, Dennis J. Slamon	33
6	Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study 2021 ·Journal of Clinical Oncology ·Nancy U. Lin, Mark D. Pegram, Solmaz Sahebjam, Nuhad K. Ibrahim, (unknown), (unknown), Alan Nicholas, Whitney P. Kirschbrown, Priya Kumthekar	67
7	Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data 2020 ·Clinical Breast Cancer ·(unknown), Caroline G. Epstein, Alexandria M. Bobe, Joshua S. K. Bell, Martin C. Stumpe, (unknown), Ameen A. Salahudeen, (unknown), (unknown), (unknown), (unknown), Catherine Igartua, Robert Huether, Ashraf Hafez, Nike Beaubier, Michael D. Axelson, Mark D. Pegram, Sarah Sammons, Joyce O’Shaughnessy, Gary A. Palmer	10
8	Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG) 2020 ·Clinical Breast Cancer ·Muaiad Kittaneh, Sunil Badve, Humberto Caldera, Robert E. Coleman, Matthew P. Goetz, Reshma Mahtani, Eleftherios P. Mamounas, Kevin Kalinsky, Elyse E. Lower, Mark D. Pegram, Michael F. Press, Hope S. Rugo, Lee S. Schwartzberg, Tiffany A. Traina, Charles L. Vogel	12
9	Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation 2018 ·Molecular Cancer Therapeutics ·Jing‐Hung Wang, Alexis V. Forterre, (unknown), Daniel O. Frimannsson, Alain Delcayre, Travis J. Antes, Bradley Efron, Stefanie S. Jeffrey, Mark D. Pegram, A. Matin	148
10	Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG) 2018 ·Breast Cancer Research and Treatment ·Jame Abraham, Humberto Caldera, Robert E. Coleman, Anthony Elias, Matthew P. Goetz, Muaiad Kittaneh, Elyse E. Lower, Reshma Mahtani, E. Mamounas, Mark D. Pegram, Hope S. Rugo, Lee S. Schwartzberg, Tiffany A. Traina, (unknown)	9
11	Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer 2016 ·Clinical Cancer Research ·José Baselga, Gail D. Lewis Phillips, Sunil Verma, Jungsil Ro, Jens Huober, Alice E. Guardino, Meghna Samant, Steve Olsen, Sanne Lysbet de Haas, Mark D. Pegram	150
12	Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831 2014 ·Cancer Immunology Research ·Nadine Norton, (unknown), Mark D. Pegram, Kathleen Tenner, Karla V. Ballman, Raphael Clynes, Keith L. Knutson, Edith A. Perez	34
13	Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer 2010 ·British Journal of Cancer ·Bernard Royer, (unknown), Mark D. Pegram, Nuhad K. Ibrahim, (unknown), (unknown), Fredrik Erlandsson, Xavier Pivot	11
14	Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer 2006 ·Breast Cancer Research and Treatment ·Mark D. Pegram	74
15	Characterization of HER2 overexpressing breast cell lines selected for long-term culture with trastuzumab 2005 ·Cancer Research ·Sumanta K. Pal, (unknown), (unknown), Malgorzata Beryt, Mark D. Pegram	3
16	Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression. 2004 ·PubMed ·Gottfried E. Konecny, Mark D. Pegram	10
17	Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/ protein and vascular endothelial growth factor 2002 ·Seminars in Oncology ·Mark D. Pegram, David Reese	60
18	Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. 2001 ·PubMed ·Gottfried E. Konecny, Michael Untch, (unknown), Rainer Kimmig, M. Gropp, P Stieber, H. Hepp, Dennis J. Slamon, Mark D. Pegram	74
19	Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. 1999 ·PubMed ·Mark D. Pegram, Dennis J. Slamon	139
20	Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. 1994 ·PubMed ·Richard J. Pietras, B M Fendly, (unknown), Mark D. Pegram, S B Howell, Dennis J. Slamon	362

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact